During the National Kidney Foundation (NKF) Spring Clinical Meetings 2025 (SCM25), Bradley Warady, MD, received the David M. Hume Award in recognition of his scholarship and humanitarianism. Dr. Warady is the McLaughlin Family Endowed Chair in Nephrology and a professor of pediatrics at the University of Missouri–Kansas City School of Medicine and serves as director of Nephrology and Dialysis and Transplantation at Children’s Mercy Kansas City.
Advertisement
Lupin's generic tolvaptan tablets are now FDA-approved for treating autosomal dominant polycystic kidney disease (ADPKD).
Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease
The primary safety endpoint of minimal SAEs was met as well as the secondary endpoint of increased fluorodopa in the putamen.
This provides rationale for the clinical evaluation of defactinib and avutometinib in the treatment of melanoma metastases.
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
Dr. Eric Dr. Bergson about the importance of head and neck cancer awareness, how to integrate screening into routine care.
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Joel Topf spoke to onconephrologist Meghan Sise about her carboplatin dosing research at SCM25.
MarkAlain Dery, DO, breaks down the pathogenesis of measles, how it presents, why it is so misunderstood, and much more.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
The Foundation for Sickle Cell Disease Research will evaluate VAS-101 in a phase 1 clinical study.
Malignant neoplasm-associated hemophagocytic lymphohistiocytosis, COVID-19, and CAR T-cell therapy can each initiate CS.
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.